Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spotting pivotal trial updates buried in a 300-page biotech filing is hard—especially when Nanobiotix’s NanoXray platform generates data across multiple tumor types. If you’re tracking cash runway, partnership milestones or dilution risk, each disclosure matters. Stock Titan gathers every Nanobiotix insider trading Form 4 transactions notice, 8-K clinical read-out, and detailed 10-K so you don’t miss a single development.
Here’s how the platform turns complexity into clarity:
- AI-powered summaries translate dense scientific language into plain English, making Nanobiotix SEC filings explained simply.
- Real-time alerts surface Nanobiotix Form 4 insider transactions real-time and highlight management’s confidence shifts.
- Interactive dashboards link trial cost lines in the Nanobiotix quarterly earnings report 10-Q filing to cash-burn metrics, offering instant Nanobiotix earnings report filing analysis.
Whether you need the Nanobiotix annual report 10-K simplified to gauge liquidity, an Nanobiotix 8-K material events explained alert for a new radiotherapy collaboration, or the latest Nanobiotix proxy statement executive compensation details, Stock Titan delivers comprehensive coverage the moment each form hits EDGAR. Investors use these insights to:
- Monitor R&D expense trends quarter over quarter
- Track Nanobiotix executive stock transactions Form 4 before key data releases
- Understand dilution potential from shelf registrations
- Compare trial timelines across oncology indications
Stop scrolling through PDFs. Start understanding Nanobiotix SEC documents with AI—and make informed decisions in minutes, not hours.
Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering 13-month Autocallable Contingent Coupon Securities linked to Freeport-McMoRan Inc. (FCX). Each $1,000 security pays a monthly contingent coupon of at least 12.30% p.a. provided FCX’s closing price on the valuation date is at or above the Coupon Barrier (69% of the initial value). If, on any monthly Autocall Date beginning after six months, FCX closes at or above its initial value, the notes are automatically redeemed at par plus the coupon.
Principal at risk: If the notes are not autocalled and FCX closes below the Final Barrier (69% of initial) on the final valuation date, investors receive a fixed number of FCX shares (or cash equivalent) based on the equity ratio, potentially worth far less than $1,000 and as little as zero. Hypothetical payouts illustrate full redemption down to a –31% underlying return and steep losses below –31.01%.
Key terms:
- Pricing date: 10-Jul-2025; Maturity: 13-Aug-2026
- Monthly valuation & coupon observation; same dates double as potential autocalldates after month 6
- No market listing; secondary liquidity uncertain
- Credit exposure to Citigroup Global Markets Holdings Inc. and the Citigroup Inc. guarantee
Principal risks: up to 100% loss of invested amount, missed coupons if FCX trades below the barrier, early redemption limiting upside to coupons, product sensitivity to FCX volatility, estimated value below issue price, tax uncertainty, and issuer conflicts of interest.
FAQ
What is the current stock price of Nanobiotix S.A. (NBTX)?
What is the market cap of Nanobiotix S.A. (NBTX)?
What is the core focus of Nanobiotix S.A.?
How does the NanoXray technology work?
Which cancer types are targeted by Nanobiotix's products?
What is NBTXR3?
How does Nanobiotix integrate its technology with traditional treatments?
What stage of development is Nanobiotix currently in?
What differentiates Nanobiotix in the oncology market?
